Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib,
dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic
myeloid leukemia cells produce a protein called BCR-ABL. The BCR-ABL protein helps chronic
myeloid leukemia cells to grow and divide. Tyrosine kinase inhibitors, such as bosutinib,
dasatinib, and nilotinib, stop the BCR-ABL protein from working, which helps to reduce the
amount of chronic myeloid leukemia cells in the body. Ruxolitinib is a different type of drug
that helps to stop the body from making substances called growth factors. Chronic myeloid
leukemia cells need growth factors to grow and divide. The addition of ruxolitinib to the
tyrosine kinase inhibitor may or may not help reduce the amount of chronic myeloid leukemia
cells in the body.